Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.
SY-5609 is a highly selective and potent oral inhibitor of the cyclin-dependent kinase 7.
Neoadjuvant nivolumab and ipilimumab produced an “unprecedented” major pathologic response rate in the NICHE-2 study, according to the lead study author.
Adding fruquintinib to best supportive care improved progression-free survival and overall survival in the FRESCO-2 trial.
A systematic review and meta-analysis sought to determine the risk of secondary primary cancer for survivors of colorectal cancer.